Elanco Animal Health Incorporated $ELAN Shares Purchased by TD Asset Management Inc

TD Asset Management Inc increased its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 94.7% in the second quarter, Holdings Channel reports. The firm owned 279,141 shares of the company’s stock after buying an additional 135,748 shares during the quarter. TD Asset Management Inc’s holdings in Elanco Animal Health were worth $3,986,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of the business. Sequoia Financial Advisors LLC acquired a new stake in Elanco Animal Health during the 2nd quarter worth $248,000. Callan Family Office LLC boosted its stake in Elanco Animal Health by 239.0% during the 2nd quarter. Callan Family Office LLC now owns 166,198 shares of the company’s stock worth $2,373,000 after purchasing an additional 117,174 shares during the period. US Bancorp DE boosted its stake in Elanco Animal Health by 188.4% during the 2nd quarter. US Bancorp DE now owns 42,986 shares of the company’s stock worth $614,000 after purchasing an additional 28,080 shares during the period. KLP Kapitalforvaltning AS boosted its stake in Elanco Animal Health by 5.2% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 101,000 shares of the company’s stock worth $1,442,000 after purchasing an additional 5,000 shares during the period. Finally, Petros Family Wealth LLC acquired a new stake in Elanco Animal Health during the 2nd quarter worth $149,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $21.75 on Tuesday. The company has a 50-day simple moving average of $19.00 and a 200-day simple moving average of $14.90. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. The company has a market capitalization of $10.81 billion, a PE ratio of 25.29, a P/E/G ratio of 3.93 and a beta of 1.65. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $21.82.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.06. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The business’s revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ELAN has been the subject of a number of analyst reports. Leerink Partnrs upgraded shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 17th. Wall Street Zen upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating in a research report on Saturday, July 5th. Zacks Research upgraded shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 3rd. Leerink Partners upgraded shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price objective for the company in a research report on Thursday, July 17th. Finally, JPMorgan Chase & Co. upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $18.00 to $24.00 in a research report on Tuesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.